A detailed history of Comprehensive Financial Consultants Institutional, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Comprehensive Financial Consultants Institutional, Inc. holds 4,555 shares of AMGN stock, worth $1.34 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
4,555
Previous 4,966 8.28%
Holding current value
$1.34 Million
Previous $1.55 Million 5.42%
% of portfolio
0.57%
Previous 0.64%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$309.38 - $337.38 $127,155 - $138,663
-411 Reduced 8.28%
4,555 $1.47 Million
Q2 2024

Jul 17, 2024

BUY
$262.75 - $319.31 $62,271 - $75,676
237 Added 5.01%
4,966 $1.55 Million
Q1 2024

May 02, 2024

SELL
$268.87 - $324.56 $14,250 - $17,201
-53 Reduced 1.11%
4,729 $1.34 Million
Q4 2023

Jan 24, 2024

BUY
$255.7 - $288.46 $15,342 - $17,307
60 Added 1.27%
4,782 $1.38 Million
Q3 2023

Nov 13, 2023

SELL
$218.65 - $271.46 $14,868 - $18,459
-68 Reduced 1.42%
4,722 $1.27 Million
Q2 2023

Jul 24, 2023

BUY
$214.27 - $253.37 $49,496 - $58,528
231 Added 5.07%
4,790 $1.06 Million
Q1 2023

Apr 19, 2023

BUY
$225.79 - $275.2 $67,511 - $82,284
299 Added 7.02%
4,559 $1.1 Million
Q4 2022

Jan 30, 2023

BUY
$229.03 - $291.01 $1,145 - $1,455
5 Added 0.12%
4,260 $1.12 Million
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $92,926 - $104,804
414 Added 10.78%
4,255 $1.08 Million
Q2 2022

Aug 09, 2022

SELL
$230.71 - $256.74 $5,075 - $5,648
-22 Reduced 0.57%
3,841 $948,000
Q1 2022

May 11, 2022

SELL
$219.27 - $242.57 $37,275 - $41,236
-170 Reduced 4.22%
3,863 $914,000
Q4 2021

Mar 10, 2022

BUY
$198.88 - $227.6 $802,083 - $917,910
4,033 New
4,033 $915,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $158B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Comprehensive Financial Consultants Institutional, Inc. Portfolio

Follow Comprehensive Financial Consultants Institutional, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comprehensive Financial Consultants Institutional, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Comprehensive Financial Consultants Institutional, Inc. with notifications on news.